CLINICAL TRIALS PROFILE FOR LIQUAEMIN LOCK FLUSH
✉ Email this page to a colleague
All Clinical Trials for LIQUAEMIN LOCK FLUSH
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05148377 ↗ | UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit. | Completed | Eurofarma Laboratorios S.A. | Phase 3 | 2007-08-01 | The objective of this study was to verify the clinical non-inferiority of the pharmacodynamic effects and the safety of use of the drug Heptar® manufactured by Eurofarma Laboratory, compared to the drug Liquemine®, manufactured by by Roche Laboratory in patients with renal failure undergoing hemodialysis treatment |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LIQUAEMIN LOCK FLUSH
Condition Name
Clinical Trial Progress for LIQUAEMIN LOCK FLUSH
Clinical Trial Phase
Clinical Trial Sponsors for LIQUAEMIN LOCK FLUSH
Sponsor Name